NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) PRO 140 Demonstrates Considerable Potential as HIV Treatment
Though considerable advances have been made in the prevention and treatment of HIV/AIDS, more than 1.2 million people in the U.S. are still affected by the disease. CytoDyn Inc.’s (OTCQB: CYDY) PRO 140 candidate is considered one of the most advanced experimental monoclonal antibodies for HIV treatment, and it has been used in more than 140 HIV-positive patients in placebo-controlled and open label FDA-approved clinical trials. “The drug has been the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test patients and has been designated a ‘fast track’ product candidate…







